ReviewACS infectious diseases2024
Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
Review in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 85 citations in OpenAlex.
- Dietary and nutritional strategies for reducing disease risk associated with antibiotic-induced dysbiosis.Gut microbes · 2026Review
- Levofloxacin enhances 5-fluorouracil efficacy in colorectal cancer by activating the DDR-TP53-mitochondrial apoptosis axis.iScience · 2026Article
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- Deep learning extracts MoA-specific signatures from high-throughput images of chemically and genetically perturbedScience advances · 2026Article
- Article
- Comparative genomic analysis of antimicrobial resistance and virulence in Escherichia coli isolated from pigeons and chickens in live poultry markets, Guiyang, China.Poultry science · 2026Article
- Article
- Solvent-driven modulation of phenolic composition and biofunctional activities of three Mentha aquatica formulations: integrated in vitro and in silico insights.Bioresources and bioprocessing · 2026Article
- Biodesulfurization and activation of a thionated levofloxacin derivative: antimicrobial evaluation and LC-MS-based metabolic profiling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Some Newer Antibiotics Active AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Antibiotic susceptibility and resistance genes in Escherichia coli from broilers reared in a low-antibiotic-use production system.Poultry science · 2026Article
- Bacterial type II topoisomerases cleave DNA in a species-specific manner.Nucleic acids research · 2026Article
- Nitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications.RSC advances · 2026Review
- Antioxidant Properties of Novel Lipophilic Fluoroquinolone Compounds Against Oxidative Stress Induced by Acetaminophen and Carbon Tetrachloride in Male Wistar Rats.Biomolecules · 2026Article
- Coordinated topoisomerase function shapes the fluoroquinolone response ofbioRxiv : the preprint server for biology · 2026Article
- Conformational analysis of different tautomers of some antibiotics.Journal of molecular modeling · 2026Article
- Article
- Preparation and antimicrobial activity of Mono-, Bis, and Tris-4,9-Dihydroxy-7,7-Dimethyl-5-(mono-substituted-aryl)-Hexahydro-Indeno[1,2-b]Indole-9,10-Dione derivatives.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Enzyme-DNA Interactions Affect the Catalytic Inhibition of Mycobacterial Gyrases by Antibacterial Drugs.ACS infectious diseases · 2026Article
- Hemoglobin-crosslinked drug-loaded silk fibroin porous scaffold for long-segment tracheal defect repair: An integrated strategy leveraging dynamic mechanical biomimicry and infection control.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Beyond their requisite functions in many critical DNA processes, the bacterial type II topoisomerases, gyrase and topoisomerase IV, are the targets of fluoroquinolone antibacterials. These drugs act by stabilizing gyrase/topoisomerase IV-generated DNA strand breaks and by robbing the cell of the catalytic activities of these essential enzymes. Since their clinical approval in the mid-1980s, fluoroquinolones have been used to treat a broad spectrum of infectious diseases and are listed among the five "highest priority" critically important antimicrobial classes by the World Health Organization. Unfortunately, the widespread use of fluoroquinolones has been accompanied by a rise in target-mediated resistance caused by specific mutations in gyrase and topoisomerase IV, which has curtailed the medical efficacy of this drug class. As a result, efforts are underway to identify novel antibacterials that target the bacterial type II topoisomerases. Several new classes of gyrase/topoisomerase IV-targeted antibacterials have emerged, including novel bacterial topoisomerase inhibitors,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.